Cargando…

Proteasome impairment in neural cells derived from HMSN-P patient iPSCs

Hereditary motor and sensory neuropathy with proximal dominant involvement (HMSN-P) is caused by a heterozygous mutation (P285L) in Tropomyosin-receptor kinase Fused Gene (TFG), histopathologically characterized by progressive spinal motor neuron loss with TFG cytosolic aggregates. Although the TFG...

Descripción completa

Detalles Bibliográficos
Autores principales: Murakami, Nagahisa, Imamura, Keiko, Izumi, Yuishin, Egawa, Naohiro, Tsukita, Kayoko, Enami, Takako, Yamamoto, Takuya, Kawarai, Toshitaka, Kaji, Ryuji, Inoue, Haruhisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5310050/
https://www.ncbi.nlm.nih.gov/pubmed/28196470
http://dx.doi.org/10.1186/s13041-017-0286-y
_version_ 1782507809359790080
author Murakami, Nagahisa
Imamura, Keiko
Izumi, Yuishin
Egawa, Naohiro
Tsukita, Kayoko
Enami, Takako
Yamamoto, Takuya
Kawarai, Toshitaka
Kaji, Ryuji
Inoue, Haruhisa
author_facet Murakami, Nagahisa
Imamura, Keiko
Izumi, Yuishin
Egawa, Naohiro
Tsukita, Kayoko
Enami, Takako
Yamamoto, Takuya
Kawarai, Toshitaka
Kaji, Ryuji
Inoue, Haruhisa
author_sort Murakami, Nagahisa
collection PubMed
description Hereditary motor and sensory neuropathy with proximal dominant involvement (HMSN-P) is caused by a heterozygous mutation (P285L) in Tropomyosin-receptor kinase Fused Gene (TFG), histopathologically characterized by progressive spinal motor neuron loss with TFG cytosolic aggregates. Although the TFG protein, found as a type of fusion oncoprotein, is known to facilitate vesicle transport from endoplasmic reticulum (ER) to Golgi apparatus at ER exit site, it is unclear how mutant TFG causes motor neuron degeneration. Here we generated induced pluripotent stem cells (iPSCs) from HMSN-P patients, and differentiated the iPSCs into neural cells with spinal motor neurons (iPS-MNs). We found that HMSN-P patient iPS-MNs exhibited ubiquitin proteasome system (UPS) impairment, and HMSN-P patient iPS-MNs were vulnerable to UPS inhibitory stress. Gene correction of the mutation in TFG using the CRISPR-Cas9 system reverted the cellular phenotypes of HMSN-P patient iPS-MNs. Collectively, these results suggest that our cellular model with defects in cellular integrity including UPS impairments may lead to identification of pathomechanisms and a therapeutic target for HMSN-P. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13041-017-0286-y) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5310050
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-53100502017-03-13 Proteasome impairment in neural cells derived from HMSN-P patient iPSCs Murakami, Nagahisa Imamura, Keiko Izumi, Yuishin Egawa, Naohiro Tsukita, Kayoko Enami, Takako Yamamoto, Takuya Kawarai, Toshitaka Kaji, Ryuji Inoue, Haruhisa Mol Brain Research Hereditary motor and sensory neuropathy with proximal dominant involvement (HMSN-P) is caused by a heterozygous mutation (P285L) in Tropomyosin-receptor kinase Fused Gene (TFG), histopathologically characterized by progressive spinal motor neuron loss with TFG cytosolic aggregates. Although the TFG protein, found as a type of fusion oncoprotein, is known to facilitate vesicle transport from endoplasmic reticulum (ER) to Golgi apparatus at ER exit site, it is unclear how mutant TFG causes motor neuron degeneration. Here we generated induced pluripotent stem cells (iPSCs) from HMSN-P patients, and differentiated the iPSCs into neural cells with spinal motor neurons (iPS-MNs). We found that HMSN-P patient iPS-MNs exhibited ubiquitin proteasome system (UPS) impairment, and HMSN-P patient iPS-MNs were vulnerable to UPS inhibitory stress. Gene correction of the mutation in TFG using the CRISPR-Cas9 system reverted the cellular phenotypes of HMSN-P patient iPS-MNs. Collectively, these results suggest that our cellular model with defects in cellular integrity including UPS impairments may lead to identification of pathomechanisms and a therapeutic target for HMSN-P. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13041-017-0286-y) contains supplementary material, which is available to authorized users. BioMed Central 2017-02-15 /pmc/articles/PMC5310050/ /pubmed/28196470 http://dx.doi.org/10.1186/s13041-017-0286-y Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Murakami, Nagahisa
Imamura, Keiko
Izumi, Yuishin
Egawa, Naohiro
Tsukita, Kayoko
Enami, Takako
Yamamoto, Takuya
Kawarai, Toshitaka
Kaji, Ryuji
Inoue, Haruhisa
Proteasome impairment in neural cells derived from HMSN-P patient iPSCs
title Proteasome impairment in neural cells derived from HMSN-P patient iPSCs
title_full Proteasome impairment in neural cells derived from HMSN-P patient iPSCs
title_fullStr Proteasome impairment in neural cells derived from HMSN-P patient iPSCs
title_full_unstemmed Proteasome impairment in neural cells derived from HMSN-P patient iPSCs
title_short Proteasome impairment in neural cells derived from HMSN-P patient iPSCs
title_sort proteasome impairment in neural cells derived from hmsn-p patient ipscs
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5310050/
https://www.ncbi.nlm.nih.gov/pubmed/28196470
http://dx.doi.org/10.1186/s13041-017-0286-y
work_keys_str_mv AT murakaminagahisa proteasomeimpairmentinneuralcellsderivedfromhmsnppatientipscs
AT imamurakeiko proteasomeimpairmentinneuralcellsderivedfromhmsnppatientipscs
AT izumiyuishin proteasomeimpairmentinneuralcellsderivedfromhmsnppatientipscs
AT egawanaohiro proteasomeimpairmentinneuralcellsderivedfromhmsnppatientipscs
AT tsukitakayoko proteasomeimpairmentinneuralcellsderivedfromhmsnppatientipscs
AT enamitakako proteasomeimpairmentinneuralcellsderivedfromhmsnppatientipscs
AT yamamototakuya proteasomeimpairmentinneuralcellsderivedfromhmsnppatientipscs
AT kawaraitoshitaka proteasomeimpairmentinneuralcellsderivedfromhmsnppatientipscs
AT kajiryuji proteasomeimpairmentinneuralcellsderivedfromhmsnppatientipscs
AT inoueharuhisa proteasomeimpairmentinneuralcellsderivedfromhmsnppatientipscs